Gateway Medical Research, Inc.
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Siler, Thomas
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
RPL554-CO-303, NCT06460493: Effect of Ensifentrine Treatment on CAT Score

Active, not recruiting
3
20
US
Ensifentrine 3mg, RPL554
Verona Pharma plc, Midwest Chest Consultants
COPD
12/24
12/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
INHALE, NCT06135324: Impairments That Affect Correct Inhaler Use in COPD

Recruiting
N/A
500
US
COPD Foundation, Viatris Inc.
COPD
12/24
07/25
Ayra, M David
No trials found
Plisco, Irwin
No trials found
Czarnik, Bruce T
No trials found
Parham, Walter
No trials found
Ansar, Azber
No trials found

Download Options